Merck’s Nuray Yurt Calls For Greater AI Education Among Regulators

Yurt Recently Moved To Merck After Over A Decade At Novartis

Nuray Yurt, Merck’s business engagement and activation lead for digital data and analytics, told In Vivo about her hopes for the future of AI regulation and how stakeholders ought to reframe their understanding of the sector.

Human and robot hands about to touch
Yurt emphasized the importance of 'human-powered AI' • Source: Shutterstock

After over a decade working in various positions at Novartis, culminating in a role as worldwide head of AI solutions, at the beginning of 2023 Nuray Yurt transferred to Merck & Co., Inc. and began to act as its business engagement and activation lead for digital data and analytics. In Vivo recently caught up with Yurt, following a talk about AI’s impact on pharma at the FT Pharma and Biotech Summit, to get her read on the state of the sector.

Europe’s AI Act – a draft mandate of which was recently endorsed by the European Parliament (Also see "EU AI Act Proposal Adopted By Parliament In Landslide Plenary Vote"...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Global Vision

UK Bets On Regulatory Innovation As Competitive Advantage In Synthetic Biology

 
• By 

The UK government has prioritized synthetic biology and created a "concierge service" for biotechs just as the US cuts science funding.

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By 

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Unpacking The Impact Of Trump’s Tariffs On Drug Pricing And Production

 
• By 

Big pharma plans to invest billions of dollars in US manufacturing to avoid tariffs proposed by the Trump Administration. However, the implementation of these plans may be delayed due to regulatory complexities and rising costs from tariffs, potentially impacting drug prices for consumers.

Barcelona’s S2 Xpeed Accelerates Hardware-Based Medtech Start-Ups From Prototype To Market

 
• By 

S2 Xpeed is driving the rapid growth of medtech and hardware start-ups in Europe. Operating under a "sweat equity" model, the program helps early-stage companies move from prototype to manufacturing readiness in exchange for equity.

More from In Vivo

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By 

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By 

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.

UK Bets On Regulatory Innovation As Competitive Advantage In Synthetic Biology

 
• By 

The UK government has prioritized synthetic biology and created a "concierge service" for biotechs just as the US cuts science funding.